

Table:

Within-trial analysis: Results from scenario analyses using discount rates of 30% and 50% applied to aflibercept and ranibizumab reflecting patient access schemes available in the UK <sup>a</sup>adjusted for baseline utility score

<b>Discount of 30% applied to aflibercept and ranibizumab drug costs</b>					
	<b>Outcome</b>	<b>Intervention Mean (SD); N</b>	<b>Comparator Mean (SD); N</b>	<b>Difference<sup>a</sup> Mean (95% CI)</b>	<b>Probability CE £20000 (£30000)</b>
<b>Aflibercept vs Ranibizumab</b>	<b>Cost (£)</b>	11,727 (2,900) ;154	10,893 (2,848) ;154	833 (203 to 1464)	-
	<b>QALY</b>	1.651 (0.2426) ;154	1.627 (0.2471) ;154	0.004 (-0.0430 to 0.0518)	-
	<b>ICER (£)</b>			189,133	0.11 (0.19)
<b>Bevacizumab vs Ranibizumab</b>	<b>Cost (£)</b>	6,227 (2,700) ;154	10,893 (2,848) ;154	-4,656 (-5,280 to -4,033)	-
	<b>QALY</b>	1.666 (0.2374) ;154	1.627 (0.2471) ;154	0.018 (-0.0282 to 0.0649)	-
	<b>ICER (£)</b>			Bevacizumab is dominant	1.00 (1.00)
<b>Aflibercept vs Bevacizumab</b>	<b>Cost (£)</b>	11,727 (2,900) ;154	6,227 (2,700) ;154	5,476 (4,837 to 6,116)	
	<b>QALY</b>	1.651 (0.2426) ;154	1.627 (0.2471) ;154	-0.015 (-0.0618 to 0.0322)	
	<b>ICER (£)</b>			Aflibercept is dominated	0.00 (0.00)
<b>Discount of 50% applied to aflibercept and ranibizumab drug costs</b>					
	<b>Outcome</b>	<b>Intervention Mean (SD); N</b>	<b>Comparator Mean (SD); N</b>	<b>Difference<sup>a</sup> Mean (95% CI)</b>	<b>Probability CE £20000 (£30000)</b>
<b>Aflibercept vs Ranibizumab</b>	<b>Cost (£)</b>	10,042 (2,553) ;154	9,499 (2,538) ;154	497 (-71 to 1,053)	-
	<b>QALY</b>	1.651 (0.2426) ;154	1.627 (0.2471) ;154	0.004 (-0.0430 to 0.0518)	-
	<b>ICER (£)</b>			111,622	0.24 (0.32)
<b>Bevacizumab vs Ranibizumab</b>	<b>Cost (£)</b>	6,201 (2,419) ;154	9,499 (2,538) ;154	-3,288 (-3,842 to -2,734)	-
	<b>QALY</b>	1.666 (0.2374) ;154	1.627 (0.2471) ;154	0.018 (-0.0282 to 0.0649)	-
	<b>ICER (£)</b>			Bevacizumab is dominant	1.00 (1.00)

<b>Aflibercept vs Bevacizumab</b>	<b>Cost (£)</b>	10,042 (2,553) ;154	6,201 (2,419) ;154	3,809 (3,252 to 4,365)	-
	<b>QALY</b>	1.651 (0.2426)	1.666 (0.2374) ;154	-0.015 (-0.0618 to 0.0322)	-
	<b>ICER (£)</b>				Aflibercept dominated